EDP-323
- Generic Name
- EDP-323
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
Phase 1
Recruiting
- Conditions
- RSV InfectionDrug Drug Interaction
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06917508
- Locations
- 🇺🇸
ICON, plc, San Antonio, Texas, United States
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
Phase 1
Recruiting
- Conditions
- RSV InfectionDrug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06847464
- Locations
- 🇺🇸
ICON, plc, San Antonio, Texas, United States
A Study of EDP-323 in Healthy Subjects
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 82
- Registration Number
- NCT05587478
- Locations
- 🇺🇸
ICON, plc., Lenexa, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath